Oncodesign Precision Medicine

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specialized in precision medicine, spun-off from its parent Oncodesign in July 2022.

OPM develops technologies to discover active molecules for use against resistant and advanced cancers. OPM technologies are based on three pillars that form the foundation of precision medicine: The OncoSNIPER technology intends to identify signatures that stratify patients refractory to cancer treatments. These signatures are then translated into therapeutic targets. The platform uses and integrates public, private, and proprietary data sources based on various artificial intelligence technologies. The second pillar Nanocyclix is based on the macrocyclisation of lead-like small molecules. This is the foundation of OPM’s drug and biomarker discovery programmes. OPM has constructed a complete platform of small molecule macrocyclic kinase inhibitors (type I) consisting of over 11,000 macrocycles, based on over 50 scaffolds and 300+ separate linkers. Thirdly, Theranostics (a combination of “therapy” and “diagnostics”) intends to diagnose and treat cancers as a unified approach. These molecules target proteins expressed on cancer cells with high selectivity, with vectors that can be small molecules, peptides, or different forms of antibodies depending on the chosen target. A linker and a chelating agent are coupled to these vectors via bioconjugation.

The company’s portfolio of products in pipeline (5 as of October 2023) are in the early clinical stages.

Key customers and partnerships

In September 2022 OPM partnered with global pharmaceutical company Servier to focus on research project ‘STarT Pancreas’ to discover new therapeutic targets for pancreatic cancer treatment.

In October 2021 TiumBio, a company specializing in R&D for rare diseases,announced the collaboration for research agreement on R&D of potential drug candidates for fibrosis. Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.

Funding and financials

In October 2023 OPM raised EUR 6 million (USD 6.6 million) in financing from several regional banks including Caisse d'Épargne Bourgogne Franche Comté, Crédit Agricole Champagne Bourgogne, and Société Générale. Bpifrance and P.C.G provided guarantees for the loan. The funds are expected to support the ongoing clinical development of its drug candidate OPM-101 for chronic immuno-inflammatory diseases and to advance the development of its technologies and product portfolio.